Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
HeartBeam, Inc. (Nasdaq: BEAT) is a medical technology company focused on developing advanced diagnostic solutions for cardiovascular disease, particularly arrhythmias and other complex heart conditions. The company operates within the medical devices and digital health industries, with an emphasis on ambulatory cardiac monitoring and diagnostic software. HeartBeam’s core value proposition centers on enabling high‑fidelity cardiac data capture outside of traditional clinical settings to support more accurate and timely diagnosis.
The company’s primary business focus is the development of its proprietary HeartBeam AIMI™ platform, which is designed to capture and analyze electrical signals of the heart using a portable, patient‑operated device paired with cloud‑based software. HeartBeam targets clinicians, healthcare systems, and diagnostic service providers, with the strategic goal of improving diagnostic yield compared to conventional single‑lead ECG monitoring. HeartBeam was founded in 2015 and has evolved from early research and development into a publicly traded company following its 2021 merger with a special purpose acquisition company, which provided capital to advance regulatory and clinical development.
Business Operations
HeartBeam operates as a single‑segment company focused on the research, development, and future commercialization of cardiac diagnostic technologies. Its operations are centered on developing hardware devices capable of capturing high‑resolution cardiac electrical signals and software algorithms that reconstruct and interpret those signals for clinical use. As of publicly available filings, the company has not reported significant commercial revenue and remains primarily engaged in product development, clinical validation, and regulatory activities.
Operations are primarily domestic within the United States, with research, engineering, and corporate functions managed internally. The company controls its proprietary device designs, signal‑processing technology, and diagnostic software. HeartBeam does not report material joint ventures or operating subsidiaries, and its business model is expected to rely on device sales, software subscriptions, and diagnostic service revenue once commercialization is achieved. Data inconclusive based on available public sources regarding large‑scale commercial partnerships.
Strategic Position & Investments
HeartBeam’s strategic direction is focused on obtaining regulatory clearances, completing clinical studies, and preparing for market entry of its diagnostic solutions. The company continues to invest heavily in research and development to enhance its vector‑based ECG technology and artificial intelligence‑driven analytics. Its growth strategy emphasizes differentiation through higher diagnostic precision compared to traditional ECG monitoring methods.
The company has not disclosed any major acquisitions or external equity investments in other companies. Capital allocation has primarily been directed toward internal technology development, intellectual property expansion, and regulatory processes. HeartBeam positions itself at the intersection of cardiac diagnostics, remote patient monitoring, and AI‑enabled healthcare, although the extent of future commercialization and adoption remains dependent on regulatory outcomes and market acceptance.
Geographic Footprint
HeartBeam is headquartered in Santa Clara, California, and its operational footprint is primarily concentrated in the United States. The company’s activities, including management, engineering, and regulatory engagement, are U.S.‑based according to public disclosures.
While HeartBeam has indicated long‑term interest in international markets, particularly where ambulatory cardiac monitoring is widely adopted, there is no verified evidence of active international operations or revenue‑generating activities outside the United States. Data inconclusive based on available public sources regarding established overseas subsidiaries or operational facilities.
Leadership & Governance
HeartBeam was founded by Branislav Vajdic, who continues to shape the company’s strategic and technological vision. The leadership team brings experience across medical devices, semiconductors, and cardiovascular care, with an emphasis on innovation, clinical validation, and regulatory discipline. The company is governed by a board of directors consistent with U.S. public company standards, as disclosed in its SEC filings.
Key executives include:
- Branislav Vajdic, PhD – Founder, President, and Chief Executive Officer
- Timothy Cruickshank – Chief Financial Officer
- Robert E. Shor, MD – Chief Medical Officer
The leadership philosophy emphasizes leveraging advanced engineering and clinical insight to address unmet needs in cardiac diagnostics, while maintaining compliance with regulatory and public company governance requirements.